Navigation Links
Willa A. Hsueh, M.D., Joins Bionovo's Scientific Advisory Board
Date:12/15/2008

EMERYVILLE, Calif., Dec. 15 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today the appointment of Willa Hsueh, M.D., to the company's Scientific Advisory Board. Dr. Hsueh has extensive experience in the design and conduct of clinical trials, basic science research and in pharmaceutical drug development.

"We are very excited to have Dr. Hsueh on the scientific advisory board as we are advancing our discovery platforms," said Isaac Cohen, O.M.D., Bionovo's Chairman and CEO. "Dr. Hsueh is currently the Director of the Diabetes Research Center at The Methodist Hospital Research Institute and Chief of the Division of Diabetes, Obesity and Lipids in the Department of Medicine at The Methodist Hospital (TMHRI), Houston, Texas. Dr. Hsueh's research has led to a number of important scientific discoveries. She was the first to elucidate the relationship between nuclear receptor regulation in obesity and diabetes and their relationship to heart disease. This scientific advancement is especially critical for menopausal women and Dr. Hsueh's research ties into Bionovo's current drug discovery platform as well as our future platform development of drugs for obesity. In addition, Dr. Hsueh's deep relationships in both industry and academia will help Bionovo with our partnership discussions and scientific collaborations."

Dr. Hsueh adds, "I am looking forward to working with Bionovo's exceptional team on their very exciting nuclear receptor discovery platform. The scientific group that has been assembled to collaborate with Bionovo is unmatched in the industry. I believe the very promising pipeline of Bionovo drug candidates will provide new and improved therapies for women."

Dr. Hsueh and her team were the first to identify a potentially protective role for the activation of nuclear receptors of the
'/>"/>

SOURCE Bionovo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Siemens Congratulates Kenneth R. Bertka, M.D., Recipient of 2007 AMDIS Award
2. Robert J. Heine, M.D., Ph.D., F.R.C.P. to Join Lilly; Distinguished Diabetes Expert to Lead Diabetes/Endocrine Medical Division
3. Charles A. Peck, M.D., F.A.C.P. Joins LifeMasters as New Medical Director Focused on Client Experience
4. Statement by Daniel W. Jones, M.D., American Heart Association President on President Bushs FY 2009 Budget Proposal
5. William F. Balistreri, M.D., honored with Distinguished Service Award by AASLD
6. Eric J. Topol, M.D., to Present Late-Breaking Lecture About Advancements in Genomics of Cardiovascular Disease at ACCs 57th Annual Scientific Session
7. Pioneering Heart Surgeon, Robert E. Michler, M.D., Appointed Chair of Surgery and Surgeon-in-Chief at Einstein and at Montefiore Medical Center
8. Dr. William S. Gruss, M.D., Says That Medical Research Shows You Can Reduce Your Risk of Cancer By Up To 77% and Reverse the Effects of Aging in A CARDIOLOGISTS GUIDE TO ... ANTI-AGING, ANTIOXIDANTS & RESVERATROL
9. Dr. Siegals(R) COOKIE DIET(TM) Creator Sanford Siegal, D.O., M.D., Weighs In on Madonnas My husband didnt want to have sex on the cookie diet Remarks
10. Jeff Bailet, M.D., Appointed to American Medical Associations Advisory Committee
11. Statement of Robert OConnor, M.D., M.P.H. Chair, American Heart Association, Emergency Cardiovascular Committee, on U.S. House of Representatives Passage of the Josh Miller HEARTS Act
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 2Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 3Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 4Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 5Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 6Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 7Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 8Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 9Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 10Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 11Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 12Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 13Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 14Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 15Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 16Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 17Lilly Outlines Innovation Strategy, Reviews Promising Pipeline of Potential Medicines and Sets 2010 Financial Guidance 18UNC awarded 246 2 million renewal grant by NIH Rare Diseases Research Network 10336 1UNC awarded 246 2 million renewal grant by NIH Rare Diseases Research Network 10336 2 Tired Doctors More Prone to Errors 59371 1 Tired Doctors More Prone to Errors 59371 2 Tired Doctors More Prone to Errors 59371 3Discover Red Mangos New Seasonal Flavor 3A Pumpkin Spice 59366 1Discover Red Mangos New Seasonal Flavor 3A Pumpkin Spice 59366 2